BRIEF-Regenxbio Enters Settlement And Release Agreement With Glaxosmithkline On March 18, 2026 - SEC Filing
REGENXBIO, Inc.
GlaxoSmithKline plc Sponsored ADR
REGENXBIO, Inc. RGNX | 0.00 | |
GlaxoSmithKline plc Sponsored ADR GSK | 0.00 |
March 20 (Reuters) - SEC Filing:
REGENXBIO INC - ENTERS SETTLEMENT AND RELEASE AGREEMENT WITH GLAXOSMITHKLINE ON MARCH 18, 2026 - SEC FILING
REGENXBIO INC - TO PAY $10.0 MILLION TO GLAXOSMITHKLINE FOR ALLEGED UNDERPAYMENT OF SUBLICENSE FEES - SEC FILING
REGENXBIO INC - SETTLEMENT AGREEMENT INCLUDES MUTUAL RELEASES OF PAST AND CERTAIN FUTURE CLAIMS - SEC FILING
REGENXBIO INC - TO CONTINUE TO PAY GSK AMOUNTS RECEIVED FROM SUBLICENSEES PURSUANT TO EXISTING SUBLICENSE AGREEMENTS - SEC FILING
Source text: [ID:n0001193125-26-117913]
Further company coverage: RGNX.O
